Meta-analysis of entecavir in lamivudine-refractory patients with chronic hepatitis B

VernacularTitle:恩替卡韦治疗拉米夫定失效慢性乙型肝炎的Meta分析
Author: Gang SHI ; Liang XIAO ; Tao TAO ; Hui CHEN
Publication Type:Journal Article
Keywords: Entecavir; Lamivudine; Viral hepatitis; Meta-analysis
From: Clinical Medicine of China 2009;25(12):1260-1263
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy of entecavir in lamivudine-refractory patients with chronic hepatitis B.Methods Literature from Medline,Embase and CBM between January 2001 to December 2008 were reviewed.Acccording to the including and excwding criteria,four randomized controlled trials (RCT) were enrolled.The results of the trials were reviewed and analysed in software Revman 4.2.Results Patients in the entecavir group enjoyed significantly higher negative conversion ratios of HBV-DNA and ALT,and positive seroconversion of HBeAg:RR were 13.90(95% CI 6.39～30.24,P＜0.00001),2.49(95% CI 1.40～4.45,P=0.002),and 3.53 (95% CI 2.85～4.38,P＜0.000 01) respectively.There was a trend for the improvement of negative conversion ratio of HBeAg (RR=2.27,95% CI 1.00～5.15,P=0.05),but the incidence of side-effects of the drugs has no difference (RR=1.05,95% CI 0.97～1.14,P=0.21).Conclusions Compared with lamivudine or placebo,entecavir can significantly decrease HBV-DNA,improve liver function and positive seroconversion ratio of HBeAg without raising the incidence of drug side-effects.